Treatment with STM2457, an inhibitor of METTL3, significantly decreased the ATP generation (Figure 2D), glucose consumption (Figure 2E), production of lactate (Figure 2F) in 5-FU resistant CRC cells. This evidence concerns the gene METTL3 and colorectal carcinoma.